Appointments at Baxter, Dendreon, Roche, Somaxon and Silence Therapeutics – People on the move
Ludwig Hantson has been appointed corporate vice president (VP) and president, international of Baxter International. Hantson was previously CEO, pharma North America at Novartis and also spent 13 years at Janssen Pharmaceutica.
Roche has promoted Luca Santarelli to head of the central nervous system (CNS) discovery and translational area (DTA). Santarelli joined Roche in 2005 and most recently held the position of global head of neuroscience, clinical research and early development (CRED).
Somaxon Pharmaceuticals has appointed Tran Nguyen as vice president (VP) and chief financial officer. Nguyen has previously worked at Metabasis Therapeutics and Ligand Pharmaceuticals.
Richard Ranieri has joined Dendreon as SVP of human resources. Before joining Dendreon Ranieri worked at Sepracor, Neurocrine Biosciences, Genencor and SmithKline Beecham.
Silence Therapeutics has named Max Herrmann as chief financial officer. Herrmann has more than 20 years experience in pharma and biotech at companies including Intercytex and Onyx Pharmaceuticals.
Ralph Whitworth has been elected to the board of directors at Genzyme. Whitworth will chair a new strategic planning and capital allocation committee tasked with reviewing the company’s mix of businesses.
Ampio Pharmaceuticals has appointed Philip Coelho to its board of directors. Coelho has experience on the boards of Catalyst of Pharmaceutical Partners and Mediware Information Systems.
Patheon has appointed Mark Kontny as president of global pharmaceutical development services (PDS) and chief scientific officer. Before joining Patheon Kontny worked at Abbott Laboratories and has also held positions at Boehringer-Ingelheim and Pfizer.
